4D Molecular Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $85,090 | $90 | $15 | $14 |
Gross Profit | 83,110 | -47,148 | -47,936 | 14 |
EBITDA | 6,225 | -55,615 | -58,290 | -51,867 |
EBIT | 10,406 | -56,876 | -59,456 | -53,621 |
Net Income | 19,397 | -56,876 | -54,658 | -47,972 |
Net Change In Cash | 85,090 | 90 | 15 | 14 |
Free Cash Flow | 27,920 | -46,407 | -43,443 | -48,389 |
Cash | 60,241 | 48,555 | 77,159 | 133,526 |
Basic Shares | 57,930 | 56,126 | 55,927 | 55,744 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $85,209 | $37 | $20,723 | $3,129 |
Gross Profit | 77,584 | 37 | -76,373 | 3,129 |
EBITDA | -151,922 | -181,136 | -108,663 | -106,152 |
EBIT | -159,547 | -187,841 | -112,867 | -110,032 |
Net Income | -140,109 | -160,868 | -100,837 | -101,076 |
Net Change In Cash | 85,209 | 37 | 20,723 | 3,129 |
Cost of Revenue | -100,650 | |||
Free Cash Flow | -109,082 | -138,371 | -78,563 | -98,221 |
Cash | 60,241 | 149,336 | 249,108 | 52,351 |
Basic Shares | 57,930 | 53,943 | 39,130 | 32,351 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $0.43 |
2025-09-30 | -$1.01 |
2025-06-30 | -$0.98 |
